Alex Bataller Torralba, MD, PhD

Peer-Reviewed Articles

1. Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Elliott M, Mangaonkar A, Matin A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Yates S, Sneider A, Dworkin E, Patel AA, Bazinet A, Senapati J, Bataller A, DiNardo C, Kadia T, Tefferi A. Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent. Am J Hematol 100(2):260-271, 2025. e-Pub 2025. PMID: 39671248.
2. Martínez-Roca, A, Jiménez-Vicente, C, Merchán, B, Castaño-Díez, S, Zugasti, I, Brillembourg, H, Bataller Torralba, A, Guijarro, F, Cortés-Bullich, A, Trigueros, A, Pérez-Valencia, AI, Gallego, C, Ballestar, N, Rodríguez-Lobato, LG, Carcelero, E, Díaz-Beyá, M, Esteve, J, Fernández-Avilés, F. At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens. Cancers 16(24), 2024. e-Pub 2024.
3. Martínez-Roca, A, Jiménez-Vicente, C, Merchán, B, Castaño-Díez, S, Zugasti, I, Brillembourg, H, Bataller Torralba, A, Guijarro, F, Cortés-Bullich, A, Trigueros, A, Pérez-Valencia, AI, Gallego, C, Ballestar, N, Rodríguez-Lobato, LG, Carcelero, E, Díaz-Beyá, M, Esteve, J, Fernández-Avilés, F. At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens. Cancers 16(24), 2024. e-Pub 2024.
4. Guerrero-Murillo, M, Rill-Hinarejos, A, Trincado, JL, Bataller Torralba, A, Ortiz-Maldonado, V, Benitez-Ribas, D, Español-Rego, M, González-Navarro, EA, Martínez-Cibrián, N, Marchese, D, Martín-Martín, L, Martín, A, Rives, S, Heyn, H, Juan, M, Urbano-Ispizua, A, Delgado, J, Orfao, A, Mereu, E, Bueno, C, Menendez, P. Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias. Cell Reports Medicine 5(11), 2024. e-Pub 2024. PMID: 39471818.
5. Gener-Ricos G, Bataller A, Rodriguez-Sevilla JJ, Chien KS, Quesada AE, Almanza-Huante E, Hammond D, Sasaki K, DiNardo C, Kadia T, Daver N, Borthakur G, Issa GC, Short NJ, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer 130(20):3452-3462, 2024. e-Pub 2024. PMID: 38896064.
6. Senapati J, Kantarjian HM, Bazinet A, Reville P, Short NJ, Daver N, Borthakur G, Bataller A, Jabbour E, DiNardo C, Haddad F, Sasaki K, Popat U, Oran B, Alousi AM, Loghavi S, Shpall E, Garcia-Manero G, Ravandi F, Kadia TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130(19):3333-3343, 2024. e-Pub 2024. PMID: 38809547.
7. Castano-Diez S, Alamo JR, Lopez-Guerra M, Gomez-Hernando M, Zugasti I, Jimenez-Vicente C, Guijarro F, Lopez-Oreja I, Esteban D, Charry P, Torrecillas V, Mont-de Torres L, Cortes-Bullich A, Bataller A, Guardia A, Munarriz D, Carcelero E, Riu G, Triguero A, Tovar N, Vela D, Bea S, Costa D, Colomer D, Rozman M, Esteve J, Diaz-Beya M. Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?. Oncologist, 2024. e-Pub 2024. PMID: 39349391.
8. Bataller A, Gener-Ricos G, Almanza-Huante E, Chien KS, Urrutia S, Bazinet A, Rodriguez-Sevilla JJ, Hammond D, Sasaki K, Takahashi K, DiNardo CD, Ravandi F, Borthakur G, Kadia TM, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Adv 8(11):2695-2706, 2024. e-Pub 2024. PMID: 38513082.
9. Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. e-Pub 2024. PMID: 38695144.
10. Chorao P, Henriques M, Villalba M, Montoro J, Balaguer-Rosello A, Gonzalez EM, Gomez MD, Gomez I, Solves P, Santiago M, Asensi P, Lamas B, Bataller A, Granados P, Eiris J, Martinez D, Louro A, Rebollar P, Perla A, Salavert M, de la Rubia J, Sanz MA, Sanz J. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 30(5):538.e1-538.e10, 2024. e-Pub 2024. PMID: 38331195.
11. Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol 11(4):e276-e286, 2024. e-Pub 2024. PMID: 38452788.
12. Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol 11(4):e287-e298, 2024. e-Pub 2024. PMID: 38548404.
13. Castano-Diez S, Pomares H, Esteban D, Guijarro F, Jimenez-Vicente C, Zugasti I, Alamo JR, Mayayo VT, Lopez-Guerra M, de la Fuente C, Charry P, Cortes-Bullich A, Bataller A, Maluquer C, Colomer D, Rozman M, Arnan M, Xicoy B, Esteve J, Diaz-Beya M. Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic. Br J Haematol 204(3):892-897, 2024. e-Pub 2024. PMID: 38013238.
14. Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
15. Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927-935, 2024. e-Pub 2024. PMID: 38113472.
16. Velasco-Hernandez T, Trincado JL, Vinyoles M, Closa A, Martinez-Moreno A, Gutierrez-Aguera F, Molina O, Rodriguez-Cortez VC, Ximeno-Parpal P, Fernandez-Fuentes N, Petazzi P, Beneyto-Calabuig S, Velten L, Romecin P, Casquero R, Abollo-Jimenez F, de la Guardia RD, Lorden P, Bataller A, Lapillonne H, Stam RW, Vives S, Torrebadell M, Fuster JL, Bueno C, Sarry JE, Eyras E, Heyn H, Menendez P. Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells. Hemasphere 8(2):e45, 2024. e-Pub 2024. PMID: 38435427.
17. Oñate, G, Pratcorona, M, Garrido, A, Artigas-Baleri, A, Bataller Torralba, A, Tormo, M, Arnan, M, Vives, S, Coll, R, Salamero, O, Vall-Llovera, F, Sampol, A, Garcia, AM, Cervera, M, Avila, SG, Bargay, J, Ortín, X, Nomdedeu, J, Esteve, J, Sierra, J. Survival improvement of patients with FLT3 mutated acute myeloid leukemia. Blood cancer journal 13(1), 2023. e-Pub 2023. PMID: 37147301.
18. Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
19. Guijarro, F, López-Guerra, M, Morata, J, Bataller Torralba, A, Paz, S, Cornet-Masana, JM, Banús-Mulet, A, Cuesta-Casanovas, L, Carbó, JM, Castaño-Díez, S, Jiménez-Vicente, C, Cortés-Bullich, A, Triguero, A, Martínez-Roca, A, Esteban, D, Gómez-Hernando, M, José Ramón Álamo, M, López-Oreja, I, Garrote, M, Risueño, RM, Tonda, R, Gut, I, Colomer, D, Díaz-Beyá, M, Esteve, J. Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome. Blood Advances 7(19):5799-5811, 2023. e-Pub 2023. PMID: 37450374.
20. Bataller A, Haddad FG, Issa GC, Sasaki K, Jabbour E, Borthakur G, Ferrajoli A, Short NJ. Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. Leuk Lymphoma 64(3):746-749, 2023. e-Pub 2023. PMID: 36657414.
21. Castaño-Díez, S, López-Guerra, M, Bosch-Castañeda, C, Bataller Torralba, A, Charry, P, Esteban, D, Guijarro, F, Jiménez-Vicente, C, Castillo-Girón, C, Cortes, A, Martínez-Roca, A, Triguero, A, Álamo, JR, Beá, S, Costa, D, Colomer, D, Rozman, M, Esteve, J, Díaz-Beyá, M. Real-World Data on Chronic Myelomonocytic Leukemia. Cancers 14(17), 2022. e-Pub 2022. PMID: 36077644.
22. Ramos-Muntada, M, Trincado, JL, Blanco, J, Bueno, C, Rodríguez-Cortez, VC, Bataller Torralba, A, Lopez-Millan, B, Schwab, C, Ortega, M, Velasco, P, Blanco, ML, Nomdedeu, J, Ramírez-Orellana, M, Minguela, A, Fuster, JL, Cuatrecasas, E, Camós, M, Ballerini, P, Escherich, G, Boer, JM, DenBoer, M, Hernández, JM, Calasanz, MJ, Cazzaniga, G, Harrison, CJ, Menendez, P, Molina, O. Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia. Molecular oncology 16(16):2899-2919, 2022. e-Pub 2022. PMID: 35726693.
23. Guijarro, F, Bataller Torralba, A, Díaz-Beyá, M, Garrido, A, Coll-Ferrà, C, Vives, S, Salamero, O, Valcárcel, D, Tormo, M, Arnan, M, Sampol, A, Castaño-Díez, S, Martinez, C, Suárez-Lledó, M, Fernández-Avilés, F, Hernández-Boluda, JC, Ribera, JM, Rovira, M, Brunet, S, Sierra, J, Esteve, J. Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. Bone marrow transplantation 57(8):1304-1312, 2022. e-Pub 2022. PMID: 35643942.
24. Bueno, C, Barrera, S, Bataller Torralba, A, Ortiz-Maldonado, V, Elliot, N, O'Byrne, S, Wang, G, Rovira, M, Gutiérrez-Agüera, F, Trincado, JL, González-González, M, Morgades, M, Sorigue, M, Bárcena, P, Zanetti, SR, Torrebadell, M, Vega-García, N, Rives, S, Mallo, M, Solé, F, Mead, A, Roberts, I, Thongjuea, S, Psaila, B, Juan, M, Delgado, J, Urbano-Ispizua, A, Ribera, JM, Orfao, A, Roy, A, Menendez, P. CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. Blood 140(1):38-44, 2022. e-Pub 2022. PMID: 35421218.
25. Oliver-Caldés, A, Soler-Perromat, JC, Lozano, E, Moreno, DF, Bataller Torralba, A, Mozas, P, Garrote, M, Setoain, X, Arostegui, JI, Yagüe, J, Tovar, N, Jiménez, R, Rodríguez-Lobato, LG, Cibeira, MT, Rosinol, L, Bladé, J, Juan, M, Fernández De Larrea, C. Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma. Frontiers in Oncology 12, 2022. e-Pub 2022. PMID: 35865461.
26. Bataller Torralba, A, Garrido, A, Guijarro, F, Oñate, G, Díaz-Beyá, M, Arnan, M, Tormo, M, Vives, S, de Llano, MQ, Coll, R, Gallardo, D, Vall-Llovera, F, Escoda, L, Garcia-Guiñon, A, Salamero, O, Sampol, A, Merchan, B, Bargay, J, Castaño-Díez, S, Esteban, D, Oliver-Caldés, A, Rivero, A, Mozas, P, López-Guerra, M, Pratcorona, M, Zamora, L, Costa, D, Rozman, M, Nomdedeu, J, Colomer, D, Brunet, S, Sierra, J, Esteve, J. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia. Blood Advances 6(4):1193-1206, 2022. e-Pub 2022. PMID: 34911079.
27. Oñate, G, Bataller Torralba, A, Garrido, A, Hoyos, M, Arnan, M, Vives, S, Coll, R, Tormo, M, Sampol, A, Escoda, L, Salamero, O, Garcia, AM, Bargay, J, Aljarilla, A, Nomdedeu, J, Esteve, J, Sierra, J, Pratcorona, M. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Advances 6(3):882-890, 2022. e-Pub 2022. PMID: 34516636.
28. Zanetti, SR, Velasco-Hernandez, T, Gutiérrez-Agüera, F, Díaz, VM, Romecin, PA, Roca-Ho, H, Sánchez-Martínez, D, Tirado, N, Baroni, ML, Petazzi, P, Torres-Ruiz, R, Molina, O, Bataller Torralba, A, Fuster, JL, Ballerini, P, Juan, M, Jeremias, I, Bueno, C, Menendez, P. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. Molecular Therapy 30(2):550-563, 2022. e-Pub 2022. PMID: 34478871.

Other Articles

1. Gener-Ricos G, Rodriguez-Sevilla JJ, Urrutia S, Bataller A, Bazinet A, Garcia-Manero G Advances in the management of higher-risk myelodysplastic syndromes: future prospects. Leuk Lymphoma 65(9):1233-1244, 2024. PMID: 38712556.
2. Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol 98(9):1383-1393, 2023. PMID: 37334870.
3. Perez-Amill, L, Bataller Torralba, A, Delgado, J, Esteve, J, Juan, M, Klein-González, N Advancing CART therapy for acute myeloid leukemia. Frontiers in immunology 14, 2023. PMID: 38098489.
4. Molina, O, Bataller Torralba, A, Thampi, N, Ribera, J, Granada, I, Velasco, P, Fuster, JL, Menendez, P Near-haploidy and low-hypodiploidy in b-cell acute lymphoblastic leukemia. Cancers 14(1), 2022. PMID: 35008193.
5. Bataller A, Montalban-Bravo G, Soltysiak KA, Garcia-Manero G The role of TGFbeta in hematopoiesis and myeloid disorders. Leukemia 33(5):1076-1089, 2019. PMID: 30816330.

Letters to the Editor

1. Gener-Ricos G, Bewersdorf JP, Loghavi S, Bataller A, Goldberg AD, Sasaki K, Famulare C, Takahashi K, Issa GC, Borthakur G, Kadia TM, Short NJ, Senapati J, Carter BZ, Patel KP, Kantarjian H, Andreeff M, Stein EM, DiNardo CD. TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma 65: 1511-1515, 2024.
2. Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol 99: 792-796, 2024.
3. Bataller A, Abuasab T, McCall D, Wang W, Cuglievan B, Issa GC, Jabbour E, Short N, DiNardo CD, Tang G, Garcia-Manero G, Kantarjian HM, Sasaki K. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. Haematologica 109: 293-297, 2024.
4. Jiménez-Vicente, C, Martínez-Roca, A, Pomares, H, Castaño-Díez, S, Guijarro, F, López-Guerra, M, Bataller Torralba, A, Esteban, D, Cortés-Bullich, A, Pérez-Valencia, AI, Guardia-Torrelles, A, Zugasti, I, Rovira, M, Fernández-Avilés, F, Colomer, D, Arnan, M, Díaz-Beyá, M, Esteve, J. Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF. Leukemia Research 135, 2023.
5. Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol 98: E281-E284, 2023.
6. Urrutia S, Li Z, Almanza E, Bataller A, Kanagal-Shamanna R, Senapati J, Sasaki K, Chien K, Montalban-Bravo G, DiNardo C, Borthakur G, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. Leukemia 37: 1397-1400, 2023.
7. Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia T, Sasaki K, Kantarjian HM, Garcia-Manero G. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. Br J Haematol 201: e25-e29, 2023.
8. Bataller A, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Urrutia S, Almanza-Huante E, Gener-Ricos G, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. Leuk Res 127: 107044, 2023.